Work

Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.9090

Authors: Arun Rajan, James L. Gulley, David R. Spigel, Nicholas Iannotti, Jason Claud Chandler, Deborah J.L. Wong, Joseph W. Leach, William Jeffery Edenfield, Ding Wang, Charles H. Redfern, Hans Juergen Grote, Anja von Heydebreck, Mary M. Ruisi, Neru Munshi, Karen Kelly

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, Sarah Cannon, Tennessee Oncology, West Cancer Center, University of California, Los Angeles, Henry Ford Hospital, Sharp Memorial Hospital, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), UC Davis Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891708169

Cites:

Cited by: 7

Related to: 10